Identification and management of tardive dyskinesia: A case series and literature review

References

• Kane JM . Tardive dyskinesia circa. Am J Psychiatry 2006;163:1316–18
   PubMed Web of Science ®Google Scholar
• Schonecker M . Paroxysmal dyskinesia as the effect of megaphen. Nervenarzt 1957;28:550–3
   PubMedGoogle Scholar
• Simpson GM , Varga E , Lee JH , Zoubok B . Tardive dyskinesia and psychotropic drug history. Psychopharmacology (Berl) 1978;58:117–24
   PubMed Web of Science ®Google Scholar
• Klawans HL , Goetz CG , Perlik S . Tardive dyskinesia: review and update. Am J Psychiatry 1980;137:900–8
   PubMed Web of Science ®Google Scholar
• Lieberman JA , Stroup TS , McEvoy JP , Swartz MS , Rosenheck RA , Perkins DO , Keefe RS , Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators . Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209–23
   PubMed Web of Science ®Google Scholar
• Correll CU , Detraux J , De Lepeleire J , De Hert M . Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry 2015;14:119–36
   PubMed Web of Science ®Google Scholar
• McKean A1 , Monasterio E . Indications of atypical antipsychotics in the elderly. Expert Rev Clin Pharmacol 2015;8:5–7
   PubMed Web of Science ®Google Scholar
• Teo JT , Edwards MJ , Bhatia K . Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis. Mov Disord 2012;27:1205–15
   PubMed Web of Science ®Google Scholar
• Lister J , Nobrega JN , Fletcher PJ , Remington G . Oxidative stress and the antipsychotic-induced vacuous chewing movement model of tardive dyskinesia: evidence for antioxidant-based prevention strategies. Psychopharmacology (Berl) 2014;231:2237–49
   PubMed Web of Science ®Google Scholar
• Bakker PR , van Harten PN , van Os J . Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions. Mol Psychiatry 2008;13:544–56
   PubMed Web of Science ®Google Scholar
• Waln O , Jankovic J . An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov (N Y) 2013
   PubMedGoogle Scholar
• Fahn S , Jankovic J , Hallett M . The tardive syndromes: Phenomenology, concepts on pathophysiology and treatment, and other neuroleptic-induced syndromes. In Fahn S , Jankovic J , Hallett M , editors. Principles and practice of movement disorders. 2nd edition. Elsevier Sanders; Philadelphia: PA: 2011. p 415–46
   Google Scholar
• Albayrak Y , Ekinci O . Duloxetine-associated tardive dyskinesia resolved with fluvoxamine: a case report. J Clin Psychopharmacol 2012;32:723–4
   PubMed Web of Science ®Google Scholar
• Birthi P , Walters C , Karandikar N . A rare case of tardive dyskinesia and akathisia induced by citalopram. PM R 2010;2:973–5
   PubMedGoogle Scholar
• Chen WY , Chen AC , Tsai SJ , Lin JJ . Reversible oro-lingual dyskinesia related to lithium intoxication. Acta Neurol Taiwan 2013;22:32–5
   PubMedGoogle Scholar
• Dressler D . Tardive dystonic syndrome induced by the calcium-channel blocker amlodipine. J Neural Transm 2014;121:367–9
   PubMed Web of Science ®Google Scholar
• Mahmoudi S1, Lévesque D, Blanchet PJ. Upregulation of dopamine D3, not D2, receptors correlates with tardive dyskinesia in a primate model. Mov Disord 2014;29:1125–33
   PubMed Web of Science ®Google Scholar
• Tenback DE , van Harten PN . Epidemiology and risk factors for (tardive) dyskinesia. Int Rev Neurobiol 2011;98:211–30
   PubMed Web of Science ®Google Scholar
• Ragheb MM , Goldberg RJ . Tardive dyskinesia in geriatric patients. Aging Health 2006;2:833–49
   Google Scholar
• Rao AS , Camilleri M . Review article: metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther 2010;31:11–19
   PubMed Web of Science ®Google Scholar
• Woods SW , Morgenstern H , Saksa JR , Walsh BC , Sullivan MC , Money R , et al. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. J Clin Psychiatry 2010;71:463–74
   PubMed Web of Science ®Google Scholar
• Jacobsen FM . Second-generation antipsychotics and tardive syndromes in affective illness: a public health problem with neuropsychiatric consequences. Am J Public Health 2015;105:e10–16
   PubMed Web of Science ®Google Scholar
• Coplan J , Gugger JJ , Tasleem H . Tardive dyskinesia from atypical antipsychotic agents in patients with mood disorders in a clinical setting. J Affect Disord 2013;150:868–71
   PubMed Web of Science ®Google Scholar
• Fernandez HH , Friedman JH . Classification and treatment of tardive syndromes. Neurologist 2003;9:16–27
   PubMed Web of Science ®Google Scholar
• Horie C , Suzuki Y , Kiyosawa M , Mochizuki M , Wakakura M , Oda K , et al. Decreased dopamine D receptor binding in essential blepharospasm. Acta Neurol Scand 2009;119:49–54
   PubMed Web of Science ®Google Scholar
• Mehanna R , Jankovic J . Respiratory disorders associated with dystonia. Mov Disord 2012;27:1816–19
   PubMed Web of Science ®Google Scholar
• Battini R , Olivieri I , Di Pietro R , Casarano M , Sgandurra G , et al. Movement disorder-childhood rating scale: a sensitive tool to evaluate movement disorders. Pediatr Neurol 2015;53:73–7
   PubMed Web of Science ®Google Scholar
• Baizabal-Carvallo JF , Stocco A , Muscal E , Jankovic J . The spectrum of movement disorders in children with anti-NMDA receptor encephalitis. Mov Disord 2013;28:543–7
   PubMed Web of Science ®Google Scholar
• Blanchet PJ , Popovici R , Guitard F , Rompre PH , Lamarche C , Lavigne GJ . Pain and denture condition in edentulous orodyskinesia: comparisons with tardive dyskinesia and control subjects. Mov Disord 2008;23:1837–42
   PubMed Web of Science ®Google Scholar
• Lindsey PL , Mehalic J . Psychotropic Medication-Induced Rabbit Syndrome. J Psychosoc Nurs Ment Health Serv 2010;1–6
   PubMed Web of Science ®Google Scholar
• Chen JJ and Swope DM . Movement Disorders. In Tisdale J , Miller D , editor. Drug-Induced Diseases: Prevention, Detection, and Management. Bethesda: American Society of Health-System Pharmacists; 2nd edition. 2010. 211–35
   Google Scholar
• Schneider SA , Dusek P , Hardy J , Westenberger A , Jankovic J . BhatiaKP. Genetics and pathophysiology of neurodegeneration with brain iron accumulation (NBIA). Current Neuropharmacol 2013;11:59–79
   PubMed Web of Science ®Google Scholar
• Baizabal-Carvallo JF , Bonnet C , Jankovic J . Movement disorders in systemic lupus erythematosus and the antiphospholipid syndrome. J Neurol Transm 2013;120:1579–89
   PubMed Web of Science ®Google Scholar
• Poewe W1 , Djamshidian-Tehrani A . Movement disorders in systemic diseases. Neurol Clin 2015;33:269–97
   PubMed Web of Science ®Google Scholar
• Baizabal-Carvallo JF , Jankovic J . Movement disorders in autoimmune diseases. Mov Disord 2012;27:935–46
   PubMed Web of Science ®Google Scholar
• Ferenci P . Whom and how to screen for Wilson disease. Expert Rev Gastroenterol Hepatol 2014;8:513–20
   PubMed Web of Science ®Google Scholar
• Khouzam HR , Battista MA , Emes R , Ahles S . Psychoses in late life: evaluation and management of disorders seen in primary care. Geriatrics 2005;60:26–33
   PubMed Web of Science ®Google Scholar
• Glazer WM , Morgenstern H , Doucette JT . Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications. J Clin Psychiatry 1993;54:133–9
   PubMed Web of Science ®Google Scholar
• Gharabawi GM , Bossie CA , Zhu Y , Mao L , Lasser RA . An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study. Schizophr Res 2005;77:129–39
   PubMed Web of Science ®Google Scholar
• Taylor D , Paton C , Kapur S . The Maudsley Manual Prescribing Guidelines. The South London and Maudsley NHS Foundation Trust & Oxleas NHS Foundation Trust; Informa Healthcare; United Kingdom: 10th edition. 2009. 87–9
   Google Scholar
• Bhidayasiri R1 , Fahn S , Weiner WJ , Gronseth GS , Sullivan KL , Zesiewicz TA ; American Academy of Neurology . Evidence-based guideline: treatment of tardive syndromes: report of the guideline development subcommittee of the American academy of neurology. Neurology 2013;81:463–9
   PubMed Web of Science ®Google Scholar
• Pringsheim T , Doja A , Belanger S , Patten S . Guidelines for pediatric TD management. Paediatr Child Health Pulsus Group Inc 2012;17:22B–30B
   PubMed Web of Science ®Google Scholar
• Lerner PP , Miodownik C , Lerner V . Tardive dyskinesia (syndrome): current concept and modern approaches to its management. Psychiatry Clin Neurosci 2015;69:321–34
   PubMed Web of Science ®Google Scholar
• Rana AQ , Chaudry ZM , Blanchet PJ . New and emerging treatments for symptomatic tardive dyskinesia. Drug Des Devel Ther 2013;7:1329–40
   PubMed Web of Science ®Google Scholar
• Jankelowitz SK . Treatment of neurolept-induced tardive dyskinesia. Neuropsychiatr Dis Treat 2013;9:1371–80
   PubMed Web of Science ®Google Scholar
• Wei HT , Lai YW , Chen MH , Chen YS . Oral-paliperidone-induced tardive dyskinesia: a case report. Gen Hosp Psychiatry 2012;34:578
   PubMedGoogle Scholar
• Zhang WF , Tan YL , Zhang XY , Chan RC , Wu HR , Zhou DF . Extract of ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2011;72:615–21
   PubMed Web of Science ®Google Scholar
• Canevelli M , Adali N , Kelaiditi E , Cantet C , Ousset PJ , Cesari M ; ICTUS/DSA Group . Effects of Gingko biloba supplementation in Alzheimer’s disease patients receiving cholinesterase inhibitors: data from the ICTUS study. Phytomedicine 2014;21:888–92
   PubMed Web of Science ®Google Scholar
• Mohanta TK , Tamboli Y , Zubaidha PK . Phytochemical and medicinal importance of Ginkgo biloba Nat Prod Res. 2014;28:746–52
   Google Scholar
• Thenganatt MA , Jankovic J . Treatment of dystonia. Neurotherapeutics 2014;11:139–52
   PubMed Web of Science ®Google Scholar
• Gardos G , Cole JO , Rapkin RM , LaBrie RA , Baquelod E , Moore P , Sovner R , et al. Anticholinergic challenge and neuroleptic withdrawal: changes in dyskinesia and symptom measures. Arch Gen Psychiatry 1984;41:1030–5
   PubMed Web of Science ®Google Scholar
• Tammenmaa IA , Sailas E , McGrath JJ , Soares-Weiser K , Wahlbeck K . Systematic review of cholinergic drugs for neuroleptic-induced tardive dyskinesia: a meta-analysis of randomized controlled trials. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:1099–107
   PubMed Web of Science ®Google Scholar
• Kane CD1 , Nuss JE , Bavari S . Novel therapeutic uses and formulations of botulinum neurotoxins: a patent review (2012 - 2014). Expert Opin Ther Pat 2015;25:675–90
   PubMed Web of Science ®Google Scholar
• Camargo CH , Cattai L , Teive HA . Pain Relief in Cervical Dystonia with Botulinum Toxin Treatment. Toxins (Basel) 2015;7:2321–35
   PubMed Web of Science ®Google Scholar
• Blanchet PJ , Popovici R , Guitard F , Rompre PH , Lamarche C , Lavigne GJ . Pain and denture condition in edentulous orodyskinesia: comparisons with tardive dyskinesia and control subjects. Mov Disord 2008;23:1837–42
   PubMed Web of Science ®Google Scholar
• Kertesz DP1 , Swartz MV , Tadger S , Plopski I , Barak Y . Tetrabenazine for tardive tremor in elderly adults: a prospective follow-up study. Clin Neuropharmacol 2015;38:23–5
   PubMed Web of Science ®Google Scholar
• LeWitt PA1 . Tardive dyskinesia caused by tetrabenazine. Clin Neuropharmacol 2013;36:92–3
   PubMed Web of Science ®Google Scholar
• Guay DR . Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders. Am J Geriatr Pharmacother 2010;8:331–73
   PubMed Web of Science ®Google Scholar
• Leung JG1 , Breden EL . Tetrabenazine for the treatment of tardive dyskinesia. Ann Pharmacother 2011;45:525–31
   PubMed Web of Science ®Google Scholar
• Kenney C , Hunter C , Jankovic J . Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord 2007;22:193–7
   PubMed Web of Science ®Google Scholar
• Farooq MU , Bhatt A , Majid A , Gupta R , Khasnis A , Kassab MY . Levetiracetam for Managing Neurologic and Psychiatric Disorders. Am J Health Syst Pharm 2009;66:541–61
   PubMed Web of Science ®Google Scholar
• Woods SW , Saksa JR , Baker CB , Cohen SJ , Tek C . Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2008;69:546–54
   PubMed Web of Science ®Google Scholar
• Factor SA . Propranolol therapy for tardive dyskinesia revisited. Mov Disord 2012;27:1703
   PubMed Web of Science ®Google Scholar
• Yaman A , Akdeniz M , Yaman H . How best to address these common movement disorders. J Fam Pract 2011;60:721–5
   PubMed Web of Science ®Google Scholar
• Aquino CC , Lang AE . Tardive dyskinesia syndromes: current concepts. Parkinsonism Relat Disord 2014;20:S113–17
   PubMedGoogle Scholar
• Abe K . Zolpidem therapy for movement disorders. Recent Pat CNS Drug Discov 2008;3:55–60
   PubMedGoogle Scholar
• Waln O , Jankovic J . Zolpidem improves tardive dyskinesia and akathisia. Mov Disord 2013;28:1748–9
   PubMed Web of Science ®Google Scholar
• Hampton LM , Daubresse M , Chang HY , Alexander GC , Budnitz DS . Emergency department visits by adults for psychiatric medication adverse events. JAMA Psychiatry 2014;71:1006–14
   PubMed Web of Science ®Google Scholar